Baxter GAMMAGARD LIQUID for PI receives FDA acceptance for subcutaneous administration Baxter International Inc. Today that the U announced acheter un produit read more .S. Food and Medication Administration has authorized the subcutaneous administration of GAMMAGARD LIQUID 10 percent [Immune Globulin Infusion ] for patients with principal immunodeficiency . The acceptance of this new path of administration allows physicians and PI individuals to interact to determine which path of administration of GAMMAGARD LIQUID can be most appropriate. Subcutaneous usage of GAMMAGARD LIQUID enables individuals to self-administer their therapy in the home on a every week basis. The FDA acceptance of a subcutaneous path of administration for GAMMAGARD LIQUID presents PI patients the choice to manage GAMMAGARD LIQUID either intravenously or subcutaneously, based on their individual requirements, stated Richard Schiff, M.D., Ph.D., medical director for Baxter’s gammaglobulin trials.
Bayer: Very successful begin to 2014 Product sales of the Bayer Group advanced by 2.8 % in the first quarter of 2014 to EUR 10,555 million . Adjusted for currency and portfolio results , business extended by 8.4 %. EBIT rose by 18.4 % to EUR 2,096 million after net special components of plus EUR 7 million . EBIT before special products elevated by 15.0 % to EUR 2,089 million . Regardless of negative currency ramifications of some EUR 200 million or roughly 8 %, EBITDA before particular items improved by 11.6 % to EUR 2,738 million .